Actively Recruiting
Neutralizing Power of Serum Antibodies - 2
Led by Centre Hospitalier Régional d'Orléans · Updated on 2025-12-19
30
Participants Needed
1
Research Sites
515 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
CONDITIONS
Official Title
Neutralizing Power of Serum Antibodies - 2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (≥18 years)
- Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
- Patients have provided written informed consent
You will not qualify if you...
- Persons under guardianship or curatorship
- Persons under legal protection
- Persons deprived of liberty
- Persons not affiliated to a social security scheme
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Orléans
Orléans, France, 45067
Actively Recruiting
Research Team
T
Thierry PRAZUCK, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here